{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:58:17Z","timestamp":1762102697029,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bbrc.2022.01.086","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T16:29:36Z","timestamp":1643387376000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effects of a novel selective PPAR\u03b1 modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model"],"prefix":"10.1016","volume":"596","author":[{"given":"Atsushi","family":"Kimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-4400","authenticated-orcid":false,"given":"Kenya","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Ohkoshi-Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Shinagawa-Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Owaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyumi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroteru","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.01.086_bib1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2022.01.086_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib3","doi-asserted-by":"crossref","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2022.01.086_bib4","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2022.01.086_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ. Open. Diabetes. Res. Care"},{"key":"10.1016\/j.bbrc.2022.01.086_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bbrc.2018.01.057","article-title":"Effect of histidine on sorafenib-induced vascular damage: analysis using novel medaka fish model","volume":"496","author":"Shinagawa-Kobayashi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2022.01.086_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/2211-5463.12598","article-title":"Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)","volume":"9","author":"Goto","year":"2019","journal-title":"FEBS. Open. Bio."},{"key":"10.1016\/j.bbrc.2022.01.086_bib9","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/2211-5463.12734","article-title":"Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease","volume":"9","author":"Nagoya","year":"2019","journal-title":"FEBS. Open. Bio."},{"key":"10.1016\/j.bbrc.2022.01.086_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1242\/dmm.002311","article-title":"Medaka as a model for human nonalcoholic steatohepatitis","volume":"3","author":"Matsumoto","year":"2010","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bbrc.2022.01.086_bib11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2022.01.086_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00441-011-1132-7","article-title":"Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation","volume":"344","author":"Kuwashiro","year":"2011","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbrc.2022.01.086_bib13","first-page":"4995","article-title":"Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model","volume":"29","author":"Vrekoussis","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2022.01.086_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2331\/suisan.80.379","article-title":"Comparison of stress response between two wild populations of Japanese medaka, Oryzias latipes and O. sakaizumii","volume":"80","author":"Mao","year":"2014","journal-title":"Nippon Suisan Gakkaishi"},{"key":"10.1016\/j.bbrc.2022.01.086_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0192623312464308","article-title":"Anchoring hepatic gene expression with development of fibrosis and neoplasia in a toxicant-induced fish model of liver injury","volume":"41","author":"Van Wettere","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome Analysis of K-877 (a Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.bbrc.2022.01.086_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205888","article-title":"Establishment of a quantitative in\u00a0vivo method for estimating adipose tissue volumes and the effects of dietary soy sauce oil on adipogenesis in medaka, Oryzias latipes","volume":"13","author":"Tonoyama","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2022.01.086_bib18","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.106.131755","article-title":"Adipose tissue and atherosclerosis: exploring the connection","volume":"27","author":"Fantuzzi","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235362","article-title":"A\u00a0novel selective PPAR\u03b1 modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms","volume":"15","author":"Kawanishi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2022.01.086_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2021.03.031","article-title":"Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH Study","volume":"20","author":"Thomson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara","year":"2016","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2022.01.086_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbrc.2022.01.086_bib23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-Week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2022.01.086_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.01.086_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.112.191593","article-title":"Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice","volume":"341","author":"Suzuki","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.bbrc.2022.01.086_bib26","doi-asserted-by":"crossref","first-page":"100807","DOI":"10.1016\/j.jbc.2021.100807","article-title":"Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide","volume":"296","author":"Kamm","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2022.01.086_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental non-alcoholic steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell. Mol.Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2022.01.086_bib28","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1038\/s41598-019-45851-3","article-title":"Versican is crucial for the initiation of cardiovascular lumen development in medaka (Oryzias latipes)","volume":"9","author":"Mittal","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:14:48Z","timestamp":1757765688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"alternative-id":["S0006291X22001127"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.01.086","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of a novel selective PPAR\u03b1 modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.01.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}